MYL
Market cap | $8.59 Billion |
---|---|
Enterprise Value | $20.18 Billion |
Dividend Yield | $0.0 (-%) |
Earnings per Share | $0.52 |
Beta | - |
Outstanding Shares | 541,546,000 |
Avg 30 Day Volume | 7,142,403 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | - |
---|---|
PEG | - |
Price to Sales | 0.0 |
Price to Book Ratio | 0.0 |
Enterprise Value to Revenue | 1.75 |
Enterprise Value to EBIT | 21.9 |
Enterprise Value to Net Income | 75 |
Total Debt to Enterprise | 0.61 |
Debt to Equity | 0.98 |
No data
No data
Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geog...